Biomedical research company Soligenix has reported encouraging interim results from an ongoing investigator-initiated study evaluating its experimental therapy HyBryte for cutaneous T-cell lymphoma (CTCL). The open-label study demonstrates potential for extended treatment effectiveness in patients with this rare disease.
The study tracked patient responses to HyBryte over an extended 54-week period, revealing significant treatment progress. Most notably, patients demonstrated a strong treatment response by week 18, which represents a notable improvement compared to existing therapies that typically require six to 12 months to show meaningful results.
CTCL remains a challenging orphan disease with limited treatment options. Soligenix CEO Christopher J. Schaber emphasized the significance of these findings, highlighting the therapy's potential to address an important unmet medical need in rare disease treatment.
Following the successful initial Phase 3 FLASH study, which established HyBryte's safety and efficacy, the company is now preparing for a confirmatory 80-patient Phase 3 FLASH 2 replication study. These ongoing research efforts suggest the potential for a novel photodynamic therapy utilizing safe visible light to treat this complex lymphoma variant.
The emerging data provides hope for patients struggling with CTCL, offering a promising pathway toward more effective and targeted treatment strategies for this rare cancer type.
